- Wondering if Arcellx at around US$114 per share still offers value, or if the easy money has already been made.
- The stock has YTD returns of 81.0% and a 1 year return of 68.7%, although the past week has been flat at around a 0.1% decline and the 30 day move sits at 0.8%.
- Recent coverage has focused on Arcellx as a higher growth biotech name, which helps explain why the share price has been so strong over the past year. That kind of attention often shifts how investors think about both the upside potential and the risks priced into the stock.
- Right now Arcellx holds a valuation score of 3/6. The rest of this article will walk through what that means across different valuation methods, before finishing with a broader way to think about what the current price is really telling you.
Approach 1: Arcellx Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and discounting them back to a present value. For Arcellx, the model used here is a 2 Stage Free Cash Flow to Equity approach built on cash flow projections in $.
The latest twelve month free cash flow stands at a loss of $213.7 million. Analyst inputs and extrapolations used by Simply Wall St project free cash flow moving from $178 million and $97.2 million losses in 2026 and 2027, to positive $84.6 million in 2028, $325.1 million in 2029 and $604.5 million in 2030, with further extrapolated growth through 2035. Discounting these projected cash flows back to today gives an estimated intrinsic value of about $489.59 per share.
With a share price around $114, the DCF output implies the stock is 76.6% undervalued on these assumptions and inputs.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Arcellx is undervalued by 76.6%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.
Approach 2: Arcellx Price vs Book
For companies that are still building toward consistent profitability, price-based metrics like the Price to Book, or P/B, ratio can be a useful way to gauge how the market values their assets and equity base. Investors often look for a P/B level that reflects both the company’s growth potential and the risks around its business model and balance sheet.
Higher growth expectations or lower perceived risk can justify a higher “normal” P/B ratio, while more uncertainty usually points to a lower one. Arcellx currently trades on a P/B of 16.71x, compared with the broader Biotechs industry average of 2.37x and a peer group average of 42.25x. That puts the stock well above the sector as a whole, but below the peer set used here.
Simply Wall St’s Fair Ratio is designed to give a more tailored reference point than simple peer or industry comparisons. It estimates what a reasonable P/B multiple could be for Arcellx after factoring in elements such as earnings growth, profit margins, risk profile, industry, and market capitalization. Comparing the Fair Ratio with the current 16.71x P/B helps indicate whether the market price looks stretched, conservative, or broadly in line with those fundamentals.
Result: ABOUT RIGHT
P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Arcellx Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, a simple framework where you spell out your story for Arcellx, link that story to a set of revenue, earnings and margin assumptions, and let the platform turn those into a Fair Value that you can compare with today’s price to help decide whether Arcellx looks attractive or stretched right now.
On Simply Wall St’s Community page, used by millions of investors, Narratives are easy to set up and refresh automatically when new information such as earnings releases or major news is added. This helps keep your view and Fair Value estimate in sync with what is happening with the company.
This approach helps you move beyond headline metrics like P/E or P/B and instead anchor every decision to a clear link between Arcellx’s story, a financial forecast and a Fair Value estimate, rather than reacting to short term price moves alone.
For Arcellx, one investor might build a Narrative that assumes stronger adoption of its treatments and a higher Fair Value, while another assumes slower progress, more conservative margins and a lower Fair Value. Both can clearly see how their expectations differ from the current share price.
Do you think there's more to the story for Arcellx? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com